Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial

Gong, Yan; Zhang, Kun; Xiong, Dongsheng; Wei, Jiajing; Tan, Hao; Qin, Shengfang

doi:10.1186/s12958-020-00648-2

Cited by 34 publications

(25 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…GH is reported to be capable of enhancing the functional mitochondria in oocytes (8), improving the proliferation and differentiation of granulosa cells (9,10) and increasing the endometrial blood perfusion as well (11). In seeking an effective approach to tackle the challenges of POR, GH has been explored in many related studies (8,(12)(13)(14) and utilized clinically for patients with POR during the ovarian stimulation for in vitro fertilization (IVF)/ intracytoplasmic sperm injection (ICSI) as well. Thus, it is crucial to ascertain the validity and specific effects of GH supplementation on the management of patients with POR.…”

Section: Introductionmentioning

confidence: 99%

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

Liu

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundPoor ovarian response (POR) remains one of the most challenging conditions in assisted reproduction technology. Previous studies seemed to indicate that growth hormone (GH) was a potential solution for the dilemma of POR; however, the role GH played on the low-prognosis patients diagnosed and stratified by the POSEIDON criteria remains indistinct.MethodsThis retrospective study was performed among women with POR according to the POSEIDON criteria who failed a previous in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycle, and the subsequent cycle was under GH cotreatment and conducted within 12 months. These participants were stratified into four groups according to the POSEIDON criteria. The comparison was implemented between the failed cycle and the cycle treated with GH. Generalized estimating equation (GEE) multivariate regression was applied for data analysis.ResultsA total of 428 low-prognosis women were included in this study. GH supplementation improved the live birth rates (47.66%, 28.33%, 45.45%, and 24.07%; in groups 1, 2, 3, and 4, respectively) and the clinical pregnancy rates (OR 19.16, 95% CI 7.87–46.63, p < 0.001; OR 7.44, 95% CI 1.65–33.55, p = 0.009; OR 10.19, 95% CI 2.39–43.52, p = 0.002; OR 27.63, 95% CI 4.46–171.11, p < 0.001; in groups 1, 2, 3, and 4, respectively) in all four POSEIDON groups. The number of oocytes retrieved was significantly elevated in the subgroups with normal ovarian reserve (IRR 1.47, 95% CI 1.36–1.59, p < 0.001; IRR 1.31, 95% CI 1.15–1.49, p < 0.001; in groups 1 and 2, respectively). The number of day-3 good-quality embryos was significantly elevated in the subgroups with either normal ovarian reserve or aged young (IRR 2.13, 95% CI 1.78–2.56, p < 0.001; IRR 1.54, 95% CI 1.26–1.89, p < 0.001; IRR 1.47, 95% CI 1.10–1.98, p = 0.010; in groups 1, 2, and 3, respectively).ConclusionGrowth hormone cotreatment could ameliorate the pregnancy outcome for women with POR under the POSEIDON criteria who failed a previous IVF/ICSI cycle. The application of growth hormone for low-prognosis women who experienced a failed cycle might be considered and further studied.

show abstract

Section: Introductionmentioning

confidence: 99%

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

Liu

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…It also corroborates the more recent ndings by Li and Gong in their randomized controlled trials to look at GH use in the setting of history of poor embryo development and poor responder patients respectively. Both studies supported the use of GH in IVF cycles [15,17]. This is contrast to the ndings by Zhu, et al who found that live birth rate was not improved with the use of GH as adjuvant treatment.…”

Section: Discussionmentioning

confidence: 63%

“…Safderin had an arm receive 2.5mg/day as well though this did not start until day 8 and another arm that received 0.1mg/day from cycle day 3 of the previous cycle [18]. Gong et al, administered 4IU/day (1.3mg) starting from Day 4 of the previous cycle [17]. In the LIGHT study, 12 IU/day (4mg) from day of stimulation [14].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Growth Hormone on In Vitro Fertilization Outcomes During Ovarian Stimulation: A Matched Cohort Study

Kurtz¹,

Clements²,

Bloom³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background. While growth hormone (GH) is commonly used as an adjuvant treatment to controlled ovarian stimulation (COS) for in vitro fertilization (IVF) cycles, the data regarding its efficacy is inconsistent. Design. A retrospective matched cohort study of poor responder patients who underwent COS without the use of GH (COS-GH) subsequently followed by COS cycles that included adjuvant GH (COS+GH) treatment. Materials and Methods. A list of all patients having filled a prescription for GH from January 2018 – March 2020 was obtained. GH was administered daily at 3mg (9IU) starting on the first day of stimulation and ending on the day of trigger. Only women who had documentation of a previous cycle without the use of GH were included in the study. Results. 182 cycles (91 patients) were included in the study, and COS-GH cycles were compared to COS+GH cycles. The total dose of gonadotropins used (5757 vs 4252 mIU, p=0.002), duration of stimulation (10.4 vs 10.1 days, p=-.045), maximum Estradiol (E2) (2411 vs 1932 pg/ml, p=0.010), endometrial thickness (11.2 vs 10.6 mm, p=0.010), number of oocytes retrieved (14.2 vs 11.8, p=0.001), number of mature oocytes (11.1 vs 9.7, p=0.028), number of blastocysts (3.98 vs 2.56, p=<0.001) and number of usable blastocysts (2.5 vs 1.6, p=<0.001) were all significantly greater in the GH group. Conclusions. Adding GH to the COS protocol in poor responder patients may lead to improvements in the number of oocytes retrieved, number of mature oocytes, endometrial thickness, number of blastocysts, the number of usable blastocysts.

show abstract

“…These modules reflected melatonin's effects on endocrine and immune regulation, anti-apoptosis, and ovarian function improvement. In addition, exogenous growth hormone administration has been shown to improve oocyte and embryo quality in IVF treatment of women with poor OR (80,81). The functional modules analysis showed that melatonin is closely related to the synthesis, secretion, and action of GH, which also supports the function of melatonin in improving OR.…”

Section: Important Pathways and Functional Modules Of Melatonin's Putative Targetsmentioning

confidence: 71%

Melatonin: Multi-Target Mechanism Against Diminished Ovarian Reserve Based on Network Pharmacology

Yang

Chen

et al. 2021

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundDiminished ovarian reserve (DOR) significantly increases the risk of female infertility and contributes to reproductive technology failure. Recently, the role of melatonin in improving ovarian reserve (OR) has attracted widespread attention. However, details on the pharmacological targets and mechanisms of melatonin-improved OR remain unclear.ObjectiveA systems pharmacology strategy was proposed to elucidate the potential therapeutic mechanism of melatonin on DOR at the molecular, pathway, and network levels.MethodsThe systems pharmacological approach consisted of target identification, data integration, network construction, bioinformatics analysis, and molecular docking.ResultsFrom the molecular perspective, 26 potential therapeutic targets were identified. They participate in biological processes related to DOR development, such as reproductive structure development, epithelial cell proliferation, extrinsic apoptotic signaling pathway, PI3K signaling, among others. Eight hub targets (MAPK1, AKT1, EGFR, HRAS, SRC, ESR1, AR, and ALB) were identified. From the pathway level, 17 significant pathways, including the PI3K-Akt signaling pathway and the estrogen signaling pathway, were identified. In addition, the 17 signaling pathways interacted with the 26 potential therapeutic targets to form 4 functional modules. From the network point of view, by regulating five target subnetworks (aging, cell growth and death, development and regeneration, endocrine and immune systems), melatonin could exhibit anti-aging, anti-apoptosis, endocrine, and immune system regulation effects. The molecular docking results showed that melatonin bound well to all hub targets.ConclusionThis study systematically and intuitively illustrated the possible pharmacological mechanisms of OR improvement by melatonin through anti-aging, anti-apoptosis, endocrine, and immune system regulation effects.

show abstract

Growth hormone alleviates oxidative stress and improves the IVF outcomes of poor ovarian responders: a randomized controlled trial

Cited by 34 publications

References 38 publications

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

Growth Hormone Cotreatment for Low-Prognosis Patients According to the POSEIDON Criteria

The Effect of Growth Hormone on In Vitro Fertilization Outcomes During Ovarian Stimulation: A Matched Cohort Study

Melatonin: Multi-Target Mechanism Against Diminished Ovarian Reserve Based on Network Pharmacology

Contact Info

Product

Resources

About